Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS
Najafi, Behzad ; Ghaderi, Hossein ; Jafari, Mehdi ; Najafi, Smaeil and Ahmad Kiadaliri, Aliasghar LU
(2015)
In Global journal of health science
7(2).
p.139-147
- Abstract
INTRODUCTION: Multiple sclerosis is a chronic and degenerative neurological disease characterized by loss of myelin sheath of some neurons in brain and spinal cord. It is associated with high economic burden due to premature deaths and high occurrence of disabilities. The aim of the current study was to determine cost effectiveness of two major products of interferon 1a in patients with relapsing-remitting multiple sclerosis.
METHOD AND MATERIALS: Altogether, 140 patients who have consumed Avonex and CinnoVex in Relapsing Remitting MS for at least two years were randomly selected (70 patients in each group). Health-related quality of life (HRQoL) was assessed using the adopted MSQoL-54 instrument. Costs were measured and valued... (More)
INTRODUCTION: Multiple sclerosis is a chronic and degenerative neurological disease characterized by loss of myelin sheath of some neurons in brain and spinal cord. It is associated with high economic burden due to premature deaths and high occurrence of disabilities. The aim of the current study was to determine cost effectiveness of two major products of interferon 1a in patients with relapsing-remitting multiple sclerosis.
METHOD AND MATERIALS: Altogether, 140 patients who have consumed Avonex and CinnoVex in Relapsing Remitting MS for at least two years were randomly selected (70 patients in each group). Health-related quality of life (HRQoL) was assessed using the adopted MSQoL-54 instrument. Costs were measured and valued from Ministry of Health and Medical Education (MOHME) perspective. Two-way sensitivity analysis was used to check robustness of the results.
RESULTS: Patients in CinnoVex group reported significantly higher scores in both physical (69.5 vs. 50.9, P<0.001) and mental (63.3 vs. 56.6, P=0.03) aspects of HRQoL than Avonex group. On the other hand, annual cost of CinnoVex and Avonex were 2410 US$ and 4515US$ per patient, respectively (P<0.001).
CONCLUSIONS: The results showed that CinnoVex was dominant option over the study period. It is suggested that results of the current study should be considered in allocating resources to MS treatments in Iran. Of course, our findings should be interpreted with caution duo to short term horizon and lack of HRQoL scores at baseline (before the intervention).
(Less)
- author
- Najafi, Behzad
; Ghaderi, Hossein
; Jafari, Mehdi
; Najafi, Smaeil
and Ahmad Kiadaliri, Aliasghar
LU
- publishing date
- 2015-03-01
- type
- Contribution to journal
- publication status
- published
- in
- Global journal of health science
- volume
- 7
- issue
- 2
- pages
- 9 pages
- publisher
- Canadian Center of Science and Education
- external identifiers
-
- scopus:84928283126
- pmid:25716386
- ISSN
- 1916-9736
- DOI
- 10.5539/gjhs.v7n2p139
- language
- English
- LU publication?
- no
- id
- 196d7cd4-fbb5-4370-90be-4da3150f4895
- date added to LUP
- 2016-11-17 13:37:42
- date last changed
- 2024-06-14 18:02:35
@article{196d7cd4-fbb5-4370-90be-4da3150f4895,
abstract = {{<p>INTRODUCTION: Multiple sclerosis is a chronic and degenerative neurological disease characterized by loss of myelin sheath of some neurons in brain and spinal cord. It is associated with high economic burden due to premature deaths and high occurrence of disabilities. The aim of the current study was to determine cost effectiveness of two major products of interferon 1a in patients with relapsing-remitting multiple sclerosis.</p><p>METHOD AND MATERIALS: Altogether, 140 patients who have consumed Avonex and CinnoVex in Relapsing Remitting MS for at least two years were randomly selected (70 patients in each group). Health-related quality of life (HRQoL) was assessed using the adopted MSQoL-54 instrument. Costs were measured and valued from Ministry of Health and Medical Education (MOHME) perspective. Two-way sensitivity analysis was used to check robustness of the results.</p><p>RESULTS: Patients in CinnoVex group reported significantly higher scores in both physical (69.5 vs. 50.9, P<0.001) and mental (63.3 vs. 56.6, P=0.03) aspects of HRQoL than Avonex group. On the other hand, annual cost of CinnoVex and Avonex were 2410 US$ and 4515US$ per patient, respectively (P<0.001).</p><p>CONCLUSIONS: The results showed that CinnoVex was dominant option over the study period. It is suggested that results of the current study should be considered in allocating resources to MS treatments in Iran. Of course, our findings should be interpreted with caution duo to short term horizon and lack of HRQoL scores at baseline (before the intervention).</p>}},
author = {{Najafi, Behzad and Ghaderi, Hossein and Jafari, Mehdi and Najafi, Smaeil and Ahmad Kiadaliri, Aliasghar}},
issn = {{1916-9736}},
language = {{eng}},
month = {{03}},
number = {{2}},
pages = {{139--147}},
publisher = {{Canadian Center of Science and Education}},
series = {{Global journal of health science}},
title = {{Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS}},
url = {{http://dx.doi.org/10.5539/gjhs.v7n2p139}},
doi = {{10.5539/gjhs.v7n2p139}},
volume = {{7}},
year = {{2015}},
}